Loading…
← CockpitCompetitor Analysis › 688580.SS Nanjing Vishee Medical Technology Co., Ltd. Class AOpen in the cockpit ↗

Nanjing Vishee Medical Technology Co., Ltd. Class A688580.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum laggard 14
Mkt cap
$499M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$6.93M
20-day average traded
Fwd P/E
19.7×
forward earnings
ROIC−WACC
+0.4 pp
WACC 11.5%
Hurdle
+16 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥35.21
1D-3.0%
1W-10.8%
1M-13.9%
3M-29.7%
6M-43.4%
YTD-27.2%
1Y-32.4%
ATR %4.8%
52w lowhigh51.3% off high

What Nanjing Vishee Medical Technology does

Employees: 635

Nanjing Vishee Medical Technology at a glance

Size Nanjing Vishee Medical Technology (688580.SS) is a China Health Care company (Medical Specialties) with a market value of $499M, the 3707th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥35.21 on 18 Nov 2026.

Performance Over six months the shares fell 43.4%, against -16.1% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 6.9% over the last twelve months (peer median +5.5%); the operating margin is 24.2% (peer median 2.5%).

Valuation It trades at 19.7× forward earnings against a peer median of 22.4× (5th cheapest of 10).

Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.4 points above its cost of capital (11.5% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 84688580.SS 58
Six months, rebased to 100: Nanjing Vishee Medical Technology against the median of its 20 peers (local-currency closes).

Nanjing Vishee Medical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥462MCN¥458MCN¥395MCN¥458MCN¥319M
Revenue growth—+16%-14%+44%—
Gross profitCN¥311MCN¥285MCN¥245MCN¥316MCN¥221M
EBITDAn/aCN¥161MCN¥106MCN¥137MCN¥85.3M
Net incomeCN¥160MCN¥138MCN¥102MCN¥136MCN¥93.8M
Free cash flowCN¥31.6MCN¥71.2MCN¥16.5MCN¥11.3MCN¥6.56M
Capital expenditureCN¥133MCN¥118MCN¥113MCN¥133MCN¥95.6M
Total debtCN¥271,321CN¥1.05MCN¥30.0MCN¥27.1MCN¥1.19M

Quarterly statements and history in the cockpit →

Nanjing Vishee Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%688298MEDX688075AVR6035207979300639002932301033NNNN300439300246CEVI603309RCELMYGNZJYL688580.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Nanjing Vishee Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×60×MEDX6035207979300639688606301033CEVI6033094549688580.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nanjing Vishee Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%MEDX688075300639688606301033300439300246CEVI603309688580.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nanjing Vishee Medical Technology is the large dot.

Nanjing Vishee Medical Technology competitors and peer comparison

How Nanjing Vishee Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nanjing Vishee Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure688580.SSPeer medianRank in peer set
1-month return-13.9%-3.8%3rd lowest of 21
6-month return-43.4%-16.1%3rd lowest of 21
Distance from 52-week high-51.3%-37.9%3rd lowest of 21
Revenue growth (TTM)+6.9%+5.5%11th highest of 21
Operating margin24.2%2.5%3rd highest of 21
Forward P/E19.7×22.4×5th cheapest of 10
Growth the price implies (Req g, 7 yrs)20.1%4.5%3rd most demanding of 10
Growth delivered (Del g)+4.2%-4.3%5th highest of 10
Hurdle (Req g minus delivered)+15.9 pp-0.5 pp3rd most demanding of 10
ROIC minus cost of capital+0.4 pp-1.6 pp6th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%19.7×20.1%+4.2%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%n/an/an/a
medmix MEDX.SWSwitzerland$494M+11%-7%6%19.4×4.5%+5.0%
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%n/a30.8%-18.6%
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%n/an/an/a
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%25.8×n/an/a
Shofu 7979.TJapan$510M+32%+9%14%13.2×n/an/a
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%57.3×0.4%-13.2%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%6.9×-6.5%-4.3%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%22.4×4.3%+24.4%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%n/a6.0%-7.7%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%n/a55.3%-4.7%
CellaVision CEVI.STSweden$477M+64%+2%23%32.6×7.1%+10.0%
AngioDynamics ANGOUnited States$476M-4%+8%-6%n/an/an/a
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%11.9×-5.9%+7.7%
AVITA Medical RCELUnited States$529M+290%+17%-34%n/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%n/an/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%n/an/an/a
Eiken Chemical 4549.TJapan$466M-20%+4%6%24.5×n/an/a

Questions

Which companies are Nanjing Vishee Medical Technology's closest peers?
The cockpit's peer set: Zhejiang Orient Gene Biotech (688298.SS), medmix (MEDX.SW), Assure Tech (Hangzhou) (688075.SS), Anteris Technologies Global (AVR), Zhejiang Starry Pharmaceutical (603520.SS), Shofu (7979.T), Guangdong Hybribio Biotech (300639.SZ), Wuhan Easy Diagnosis Biomedicine (002932.SZ).
Is Nanjing Vishee Medical Technology expensive compared with its peers?
On forward p/e it trades at 19.7× against a peer median of 22.4×, 5th cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Nanjing Vishee Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -43.4% against -16.1% for the median peer; over one year -32.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.